PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025. Company Webcast The webcast presentation will take... Read More

PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX 100 , with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a... Read More

PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM... Read More

PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025. Citizens Life Sciences Conference Fireside Chat Date: Wednesday, May 7,... Read More

PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II Phase 3 trial for D-PLEX 100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery. This milestone follows recommendation by... Read More

PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the 37 th Annual ROTH Conference taking place in Dana Point, California, from March 17-18, 2025. PolyPid’s fireside chat will be available on-demand beginning on Monday, March 17,... Read More

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients to Date; Enrollment Completion Expected in March 2025, with Top-Line Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrants Expected to Extend Cash Runway Beyond Potential NDA... Read More

PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025. Oppenheimer 35 th Annual Healthcare Life Sciences Conference... Read More

PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 12, 2025. The Company will host a conference call and... Read More

630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX 100 under Fast Track and Breakthrough Therapy Designations, Previously Granted to D-PLEX 100 by the FDA; Proceeds from this Financing and Exercise of Data-Triggered Warrant Expected to Extend Cash... Read More

PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. (“ImmunoGenesis”), a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development... Read More

PETACH TIKVA, Israel, Nov. 29, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notification (the "Notification Letter") from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum... Read More

Last Patient Enrolled for Planned Unblinded Interim Analysis in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 Unblinded Interim Analysis Outcome Expected Later this Quarter SHIELD II Enrollment Completion Expected in December 2024 with Top-Line Results Anticipated in First Quarter of 2025 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD)... Read More

PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd . (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in investor meetings at the Craig-Hallum 15 th Annual Alpha Select Conference on November 19, 2024, in New York, NY. Investors interested in meeting with PolyPid should contact the... Read More

PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 13, 2024. The Company will host a conference call and webcast at 8:30 AM... Read More

SHIELD I Study is One of the Largest Phase 3 Trials in the Prevention of SSIs in Colorectal Resection Conducted in Over a Decade Pre-Specified and Post-Hoc Analyses Suggested that D-PLEX 100 May Benefit Patients with Increased SSI Risk, Including Those with Lengthy Incisions SHIELD II Study, the Ongoing Second Phase 3 with D-PLEX 100 , Focuses on Patients with Large Surgical Incisions; Top-line Results Expected in Q1 2025... Read More

Unblinded Interim Analysis to be Conducted During the Current Quarter Top-line Results Anticipated in First Quarter of 2025 PETACH TIKVA, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the last patient required in order to conduct the planned unblinded interim analysis... Read More

PETACH TIKVA, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in the following three investor conferences: H.C. Wainwright 26 th Annual Global Investment Conference PolyPid’s presentation will be available on-demand beginning on Monday,... Read More

Approximately 320 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up, Which is Expected in Fourth Quarter of 2024; Top-Line Results Anticipated in First Quarter of 2025 Recent Successful Financing of Up to $14 Million Extends Company’s... Read More

Funding Extends Company’s Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More than 300 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up... Read More

PETACH TIKVA, Israel, July 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 14, 2024. The Company will host a conference call and webcast at 8:30 AM... Read More

After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their... Read More

Charles E. Edmiston, Ph.D., Emeritus Professor of Surgery, Medical College of Wisconsin, to discuss the significant unmet medical need in surgical site infections prevention Company to Provide an Update on SHIELD II Phase 3 Study Enrollment During Event PETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical... Read More

More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Approximately 50 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 08,... Read More

PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024. Citizens JMP Life Sciences Conference Presentation Date: Monday, May 13, 2024 Time: 2:30 PM ET... Read More

Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Second Half of 2024 PETACH TIKVA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today... Read More

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM... Read More

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26 th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024. Barclays 26 th Annual Global Healthcare Conference... Read More

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal... Read More

Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Recent Successful $16 Million Financing Extends Company’s Cash Runway Through Late Q3 2024 and Beyond Expected Timing of Unblinded Interim Analysis; Potential Additional $19 Million if Warrants are Exercised to Fund PolyPid to the... Read More

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and... Read More

PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the “PIPE”) for $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of January 2, 2024 of $4.81 per... Read More

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of D-PLEX 100 Successful Completion of Good Manufacturing Practice Audit of Company’s Manufacturing Facility Conference Call Scheduled for Today at 8:30 AM ET... Read More

PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive... Read More

PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30 AM... Read More

PETACH TIKVA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2),... Read More

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX 100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA. American College of Surgeons... Read More

Safety Profile of D-PLEX 100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX 100 in Pediatric Population PETACH TIKVA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the publication of positive preclinical results... Read More

PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company’s management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York. Cantor Global Healthcare Conference: Presentation Date: Thursday, September 28,... Read More

PETACH TIKVA, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Israeli Ministry of Health has completed a successful Good Manufacturing Practice (GMP) audit of the Company's manufacturing facility without any critical or major findings. The audit was conducted as part of the... Read More

PETACH TIKVA, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, such that each thirty (30) Ordinary Shares, shall be consolidated... Read More

Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX 100 NDA and MAA Regulatory Filings PETACH TIKVA, Israel, Sept. 19, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the... Read More

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of Current Quarter Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) --... Read More

PETACH TIKVA, Israel, July 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 9, 2023. The Company will host a conference call and webcast at 8:30 AM... Read More

Potent Antibacterial Efficacy of D-PLEX 100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains D-PLEX 100 Antibacterial Activity Attributed to its Ability to Support High and Prolonged Local Antibiotic Concentration Directly at the Surgical Site PETACH TIKVA, Israel, June 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a... Read More

Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the first patient has been recruited and is scheduled for surgery in its revised SHIELD II Phase 3 trial evaluating D-PLEX... Read More

PETACH TIKVA, Israel, June 05, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s ("Nasdaq") minimum bid price rule and approval from Nasdaq to transfer the listing of the ordinary shares of the Company (the... Read More

Recruitment to Resume Imminently Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, May 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the U.S. Food and Drug Administration (FDA) agreed to Company’s SHIELD II Phase 3 trial design evaluating D-PLEX 100 for the prevention of abdominal... Read More

Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections; Recruitment Expected to Resume Imminently Received Advice from the Swedish Medical Products Agency Consistent with Feedback Received from the FDA Completed a Series of Transactions to Further Solidify Financial Position and Extend Cash Runway to Late in Q1 2024 Strengthened... Read More

PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 10, 2023. The Company will host a conference call and webcast at 8:30 AM... Read More

PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences: Aegis Capital Corp. Virtual Conference Presentation Date: Wednesday, May 3, 2023 Presentation Time: 10:30 AM Eastern Time Sidoti &... Read More

PETACH TIKVA, Israel, April 14, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing... Read More

Company Also Restructures Existing Kreos Loan, Deferring Over $3 Million of Repayment PETACH TIKVA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the closing of an underwritten public offering (the “Public Offering”) of ordinary shares, no par value, (“Ordinary Shares”) with gross... Read More

PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the pricing of an underwritten public offering of 14,660,000 ordinary shares, no par value (the “Ordinary Shares”) at a public offering price of $0.42 per share (the “Public Offering”). The gross proceeds to PolyPid from the... Read More

PETACH TIKVA, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that it has commenced an underwritten public offering of its ordinary shares, no par value (the “Ordinary Shares”). In addition, PolyPid intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the... Read More

PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023. Barclays Global Investor Conference: Presentation Date: Tuesday, March 14, 2023 Presentation Time:... Read More

Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 2023 into Ongoing SHIELD II Trial, which will be Enriched with Approximately 550 Additional Patients to Complete Clinical Testing for Potential NDA Top-line Results from SHIELD II Trial Anticipated mid-2024 Conference... Read More

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 8, 2023. The Company will host a conference call and webcast... Read More

Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA FDA Acknowledged that SHIELD I Pre-specified Subgroup Results May Provide Supportive Evidence and Proposed that Current SHIELD II Trial Could Potentially Serve to Complete Clinical Testing for NDA FDA Also Recognized that D-PLEX 100 ’s Proposed Indication is for the Prevention of Infection and Has the Potential for Wide Use... Read More

D-PLEX 100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care Results Consistent with SHIELD I Phase 3 Post-hoc Analysis Demonstrating Significant Primary Endpoint Reduction in Patients with One or More patient related Risk Factors PETACH TIKVA, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a... Read More

Meeting Scheduled for January 2023 PolyPid Recently Provided FDA with Currently Available Data from Completed SHIELD I Phase 3 Study in Advance of Meeting PETACH TIKVA, Israel, Dec. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that a Type D meeting has been scheduled for January 2023 with the U.S.... Read More